Ryght's first LinkedIn Live session discusses how GenAI is transforming clinical development, particularly within Contract Research Organizations (CROs) and trial sponsors.
Tyrone Richardson, Ryght's Chief Commercial Officer, is joined by Megan Liles, Principal Consultant at Liles Clinical Trial Consulting, who brings over 25 years of experience in global project management and innovative technology implementation.
The session explores how GenAI accelerates innovation and addresses long-standing challenges in clinical development. Richardson and Liles delve into the complexities of clinical trials, highlighting technology's role in overcoming common obstacles.
About Ryght
Ryght is a privately held healthcare technology company based in Anaheim, California that is developing the next generation of safe and secure generative artificial intelligence (GenAI) solutions for the biopharma industry. The Ryght platform leverages and optimizes multiple large language models (LLMs) and vector databases to ingest real-time data streams and make actionable knowledge directly available to biopharma discovery, clinical, and commercial teams. The platform enables healthcare professionals to rapidly leverage the power of GenAI within compliance of data security standards required by the industry.
Follow the company on 